Pharmacy News

Today's Pharmaceutical and Pharmacy News

Daily News Topic:

FDA News

9/5/10 - Ascension Orthopedics wins FDA approval for Titan modular total shoulder system

Ascension Orthopedics, a developer of PyroCarbon orthopedic devices, has received FDA approval to market the Titan modular total shoulder system. According to the company, the Titan modular total shoulder system offers a bone-preserving option for patients needing total or hemi shoulder arthroplasty.

9/4/10 - CSL Behring Receives FDA Approval to Extend Shelf Life of HizentraÂ® from 18 Months to 24 Months

CSL Behring announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of HizentraÂ®, Immune Globulin Subcutaneous, 20% Liquid, from 18 months to 24 months. Stabilized with L-proline, a naturally occurring amino acid, Hizentra can be stored at room temperature for up to 24

9/3/10 - GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta belimumab as a potential treatment for systemic lupus...

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta belimumab as a potential treatment for systemic lupus erythematosus.

9/3/10 - Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTAÂ® belimumab as a Potential Treatment for Systemic...

Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTAÂ® belimumab as a Potential Treatment for Systemic Lupus Erythematosus. Human Genome Sciences, Inc. and GlaxoSmithKline PLC announced that the U.S. Food and Drug Administration has granted a priority review designation to BENLYSTAÂ® as a potential treatme

9/2/10 - Abbott receives FDA approval to market Abbott RealTime HBV assay

Abbott, a healthcare company engaged in the discovery, development, manufacture and marketing of pharmaceuticals and medical products, has received approval from the US Food and Drug Administration, or FDA, to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus, or HBV, in a patient's blood.

9/2/10 - Actavis receives FDA approval to market ADHD drug

Actavis, a US-based manufacturing and marketing unit of generics firm Actavis Group, has received approval from the US Food and Drug Administration, or FDA, to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder, or ADHD. Actavis intends to market Atomoxetine HCl in 10mg, 18mg, 25mg, 40mg, 60mg, 80mg and 10

Chain Drug Review

Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.

Featured Article from Chain Drug Review:

AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more